Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).

被引：52

作者：

Antill, Yoland Catherine

Kok, Peey Sei

Robledo, Kristy

Barnes, Elizabeth

Friedlander, Michael

Baron-Hay, Sally E.

Shannon, Catherine M.

Coward, Jermaine

Beale, Philip James

Goss, Geraldine

Meniawy, Tarek

Yip, Sonia

Smith, Deborah

Spurdle, Amanda B.

Parry, Michelle

Andrews, John

Kelly, Marzena

Stockler, Martin R.

Mileshkin, Linda R.

机构：

[1] Cabrini Hlth, Malvern, Australia

[2] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia

[3] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia

[4] Prince Wales Hosp, Dept Med Oncol, Sydney, NSW, Australia

[5] Royal North Shore Hosp, Dept Med Oncol, St Leonards, NSW, Australia

[6] Mater Canc Care Ctr, South Brisbane, Qld, Australia

[7] Icon Canc Care, Brisbane, Qld, Australia

[8] Chris OBrien Lifehouse, Sydney, NSW, Australia

[9] Monash Med Ctr, Melbourne, Vic, Australia

[10] Sir Charles Gairdner Hosp, Perth, WA, Australia

[11] Sydney Catalyst Translat Canc Res Ctr, Sydney, NSW, Australia

[12] Univ Queensland, Mater Res Inst, Brisbane, Qld, Australia

[13] QIMR, Brisbane, Qld, Australia

[14] NHMRC Clin Trials Ctr, Camperdown, NSW, Australia

[15] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.5501

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5501

引用

页数：2